Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.

Rossi EA, Rossi DL, Cardillo TM, Stein R, Goldenberg DM, Chang CH.

Blood. 2011 Aug 18;118(7):1877-84. doi: 10.1182/blood-2011-03-343145. Epub 2011 Jun 16.

PMID:
21680794
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells.

Rossi EA, Rossi DL, Stein R, Goldenberg DM, Chang CH.

Cancer Res. 2010 Oct 1;70(19):7600-9. doi: 10.1158/0008-5472.CAN-10-2126. Epub 2010 Sep 28.

PMID:
20876805
[PubMed - indexed for MEDLINE]
Free Article
3.

CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.

Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH.

Blood. 2009 Oct 29;114(18):3864-71. doi: 10.1182/blood-2009-06-228890. Epub 2009 Aug 26.

PMID:
19710501
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.

Stein R, Qu Z, Chen S, Solis D, Hansen HJ, Goldenberg DM.

Blood. 2006 Oct 15;108(8):2736-44. Epub 2006 Jun 15.

PMID:
16778139
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.

Xuan C, Steward KK, Timmerman JM, Morrison SL.

Blood. 2010 Apr 8;115(14):2864-71. doi: 10.1182/blood-2009-10-250555. Epub 2010 Feb 4.

PMID:
20139095
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.

Loisel S, André PA, Golay J, Buchegger F, Kadouche J, Cérutti M, Bologna L, Kosinski M, Viertl D, Delaloye AB, Berthou C, Mach JP, Boumsell L.

Mol Cancer. 2011 Apr 19;10:42. doi: 10.1186/1476-4598-10-42.

PMID:
21504579
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.

Stein R, Gupta P, Chen X, Cardillo TM, Furman RR, Chen S, Chang CH, Goldenberg DM.

Blood. 2010 Jun 24;115(25):5180-90. doi: 10.1182/blood-2009-06-228288. Epub 2010 Jan 25.

PMID:
20101022
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.

DeNardo GL, Tobin E, Chan K, Bradt BM, DeNardo SJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7075s-7079s.

PMID:
16203805
[PubMed - indexed for MEDLINE]
Free Article
9.

Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells.

Nagy ZA, Hubner B, Löhning C, Rauchenberger R, Reiffert S, Thomassen-Wolf E, Zahn S, Leyer S, Schier EM, Zahradnik A, Brunner C, Lobenwein K, Rattel B, Stanglmaier M, Hallek M, Wing M, Anderson S, Dunn M, Kretzschmar T, Tesar M.

Nat Med. 2002 Aug;8(8):801-7. Epub 2002 Jul 8.

PMID:
12101408
[PubMed - indexed for MEDLINE]
10.

Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia.

DeNardo GL, Mirick GR, Hok S, DeNardo SJ, Beckett LA, Adamson GN, Balhorn RL.

Int J Oncol. 2009 Feb;34(2):511-6.

PMID:
19148487
[PubMed - indexed for MEDLINE]
11.

Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging.

DeNardo GL, Natarajan A, Hok S, Mirick G, DeNardo SJ, Corzett M, Sysko V, Lehmann J, Beckett L, Balhorn R.

Cancer Biother Radiopharm. 2008 Dec;23(6):783-96. doi: 10.1089/cbr.2008.0589.

PMID:
20443696
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties.

Fioravanti J, González I, Medina-Echeverz J, Larrea E, Ardaiz N, González-Aseguinolaza G, Prieto J, Berraondo P.

Hepatology. 2011 Jun;53(6):1864-73. doi: 10.1002/hep.24306. Epub 2011 May 2.

PMID:
21425312
[PubMed - indexed for MEDLINE]
13.

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.

Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM.

Clin Cancer Res. 2004 Apr 15;10(8):2868-78.

PMID:
15102696
[PubMed - indexed for MEDLINE]
Free Article
14.

Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines.

Tobin E, Denardo G, Zhang N, Epstein AL, Liu C, Denardo S.

Leuk Lymphoma. 2007 May;48(5):944-56.

PMID:
17487739
[PubMed - indexed for MEDLINE]
15.

Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cells.

Ding GQ, Yu YL, Shen ZJ, Zhou XL, Chen SW, Liao GD, Zhang Y.

J Zhejiang Univ Sci B. 2012 May;13(5):335-41. doi: 10.1631/jzus.B1100366.

PMID:
22556170
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.

Liu C, DeNardo G, Tobin E, DeNardo S.

Cancer Biother Radiopharm. 2004 Oct;19(5):545-61.

PMID:
15650447
[PubMed - indexed for MEDLINE]
17.

IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.

Carlo-Stella C, Guidetti A, Di Nicola M, Lavazza C, Cleris L, Sia D, Longoni P, Milanesi M, Magni M, Nagy Z, Corradini P, Carbone A, Formelli F, Gianni AM.

Cancer Res. 2007 Apr 1;67(7):3269-75.

PMID:
17409435
[PubMed - indexed for MEDLINE]
Free Article
18.

Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.

Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur DS, Gopal AK, Press OW.

Cancer Res. 2007 Jun 15;67(12):5921-8.

PMID:
17575162
[PubMed - indexed for MEDLINE]
Free Article
19.

Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.

Gupta P, Goldenberg DM, Rossi EA, Chang CH.

Blood. 2010 Oct 28;116(17):3258-67. doi: 10.1182/blood-2010-03-276857. Epub 2010 Jul 13.

PMID:
20628151
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.

Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH.

Blood. 2009 Jun 11;113(24):6161-71. doi: 10.1182/blood-2008-10-187138. Epub 2009 Apr 16.

PMID:
19372261
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk